The therapeutic benefit of growth hormone (GH) therapy in improving height in short children is widely recognized; however, GH therapy is associated with other metabolic actions that may be of benefit in these children. Beneficial effects of GH on body composition have been documented in several different patient populations as well as improvements in lipid profile. Marked augmentation of bone mineral density also seems evident in many pediatric populations. Some of these benefits may require continued therapy past the acquisition of adult height. With long-term therapy of any kind, the adverse consequences of treatment should also be considered. Fortunately, long-term GH treatment seems to be safe and well-tolerated. This review describes the long-term metabolic effects of GH treatment in the pediatric population and considers how these may benefit children who are treated with GH.
Growth Hormone: Health Considerations Beyond Height Gain
FINANCIAL DISCLOSURE: All authors are members of the Global Norditropin Advisory Panel. Dr Reiter is a consultant for Novo Nordisk, Altus, and Indevus; Dr Kiess is a member of the advisory board and received grant support from Novo Nordisk, Pfizer, Serono, and Ipsen; Dr Colao has no financial relationships relevant to this article to disclose; Dr Biller has received research grants from Eli Lilly, Novo Nordisk, Pfizer and consultant/advisory honoraria from Novo Nordisk, Pfizer, and Serono; Dr Czernichow is a consultant for Novo Nordisk, Pfizer, and Ipsen; Dr Ross is a consultant for Novo Nordisk and Eli Lilly and has received research grants from Novo Nordisk, Eli Lilly, and Pfizer.
- Views Icon Views
- Share Icon Share
- Search Site
Judith Ross, Paul Czernichow, Beverly M. K. Biller, Annamaria Colao, Ed Reiter, Wieland Kiess, on behalf of the participants in the advisory panel meeting on the effects of growth hormone; Growth Hormone: Health Considerations Beyond Height Gain. Pediatrics April 2010; 125 (4): e906–e918. 10.1542/peds.2009-1783
Download citation file: